Both in vitro, in vivo and clinical studies have shown that the level of TMEM88 is significantly increased in platinum-resistant ovarian cancer xenograft nude mice, platinum-resistant ovarian cancer cells and recurrent ovarian cancer tissue, while knockdown or decrease the expression of TMEM88 can resensitize tumor cells to platinum drugs. This evidence concerns the gene TMEM88 and ovarian cancer.